[Fundamental and clinical studies of sulbactam/cefoperazone in the pediatric field]. 1984

S Iwata, and Y Sato, and Y Iwasaki, and S Hayano, and R Wakabayashi, and Y Kojima, and H Akita, and K Sunakawa, and T Oikawa, and M Osano

Fundamental and clinical studies were carried out on sulbactam/cefoperazone (SBT/CPZ) in the field of pediatrics. The following results were obtained: A total of 185 clinical isolates that had been stocked at our department was employed to determine the minimum inhibitory concentrations (MICs) of SBT/CPZ against various bacterial species. SBT/CPZ showed strong antibacterial potency against E. coli, Salmonella, Klebsiella and P. mirabilis, and relatively strong potency against S. marcescens, P. aeruginosa and S. aureus. Antibacterial potency of SBT/CPZ was stronger than that of CPZ alone against E. coli, and it also showed strong activity against strains of Salmonella, S. marcescens and S. aureus, moderately or highly resistant to CPZ. SBT/CPZ was administered by intravenous bolus infusion to pediatric patients to determine the serum concentrations of SBT and CPZ. At a dose of 10 mg/kg the mean serum levels of SBT and CPZ were as follows; 17.8 micrograms/ml, 40.7 micrograms/ml at 15 minutes and 0.3 microgram/ml at 6 hours, respectively. The half-lives of SBT and CPZ in the serum were 1.05 hours and 1.76 hours, respectively. Similarly, at a dose of 20 mg/kg the mean serum levels of SBT and CPZ were; 31.9 micrograms/ml, 81.0 micrograms/ml at 15 minutes and 0.5 microgram/ml, 6.1 micrograms/ml at 6 hours, and the half-lives were 1.00 hour and 1.72 hours, respectively. At a dose of 40 mg/kg, only 1 case was determined. The serum levels of SBT and CPZ were 34.4 micrograms/ml, 74.8 micrograms/ml at 30 minutes and 0.2 microgram/ml at 6 hours, and the half-lives were 0.78 hour and 1.38 hours, respectively. SBT/CPZ was drip-infused intravenously over a period of 1 hour, and the serum concentrations of SBT and CPZ were determined. At the dose of 10 mg/kg or 20 mg/kg, the peak serum levels of SBT and CPZ were observed at 1 hour or at the end of drip infusion. At a dose of 10 mg/kg the mean serum levels of SBT and CPZ were 14.4 micrograms/ml, 33.7 micrograms/ml at 1 hour and 1.4 micrograms/ml, 4.6 micrograms/ml at 7 hours, respectively. The half-lives was 1.86 hours for SBT and 2.23 hours for CPZ, respectively. Similarly at a dose of 20 mg/kg, the mean serum levels of SBT and CPZ were, 22.2 micrograms/ml, 34.6 micrograms/ml at 1 hour and 0.5 microgram/ml, 2.8 micrograms/ml at 7 hours, and the half-lives was 1.17 hours and 1.75 hours, respectively. The urinary recovery rate was determined for the 6 hours period after administration.(ABSTRACT TRUNCATED AT 400 WORDS)

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D010397 Penicillanic Acid A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed) Acid, Penicillanic
D002438 Cefoperazone Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections. Cefobid,Cefoperazon,Cefoperazone Sodium,Cefoperazone Sodium Salt,Céfobis,T-1551,T1551,Salt, Cefoperazone Sodium,Sodium Salt, Cefoperazone,Sodium, Cefoperazone,T 1551
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females

Related Publications

S Iwata, and Y Sato, and Y Iwasaki, and S Hayano, and R Wakabayashi, and Y Kojima, and H Akita, and K Sunakawa, and T Oikawa, and M Osano
October 1984, The Japanese journal of antibiotics,
S Iwata, and Y Sato, and Y Iwasaki, and S Hayano, and R Wakabayashi, and Y Kojima, and H Akita, and K Sunakawa, and T Oikawa, and M Osano
October 1984, The Japanese journal of antibiotics,
S Iwata, and Y Sato, and Y Iwasaki, and S Hayano, and R Wakabayashi, and Y Kojima, and H Akita, and K Sunakawa, and T Oikawa, and M Osano
October 1984, The Japanese journal of antibiotics,
S Iwata, and Y Sato, and Y Iwasaki, and S Hayano, and R Wakabayashi, and Y Kojima, and H Akita, and K Sunakawa, and T Oikawa, and M Osano
November 1984, The Japanese journal of antibiotics,
S Iwata, and Y Sato, and Y Iwasaki, and S Hayano, and R Wakabayashi, and Y Kojima, and H Akita, and K Sunakawa, and T Oikawa, and M Osano
October 1984, The Japanese journal of antibiotics,
S Iwata, and Y Sato, and Y Iwasaki, and S Hayano, and R Wakabayashi, and Y Kojima, and H Akita, and K Sunakawa, and T Oikawa, and M Osano
October 1984, The Japanese journal of antibiotics,
S Iwata, and Y Sato, and Y Iwasaki, and S Hayano, and R Wakabayashi, and Y Kojima, and H Akita, and K Sunakawa, and T Oikawa, and M Osano
October 1984, The Japanese journal of antibiotics,
S Iwata, and Y Sato, and Y Iwasaki, and S Hayano, and R Wakabayashi, and Y Kojima, and H Akita, and K Sunakawa, and T Oikawa, and M Osano
November 1984, The Japanese journal of antibiotics,
S Iwata, and Y Sato, and Y Iwasaki, and S Hayano, and R Wakabayashi, and Y Kojima, and H Akita, and K Sunakawa, and T Oikawa, and M Osano
October 1984, The Japanese journal of antibiotics,
S Iwata, and Y Sato, and Y Iwasaki, and S Hayano, and R Wakabayashi, and Y Kojima, and H Akita, and K Sunakawa, and T Oikawa, and M Osano
November 1984, The Japanese journal of antibiotics,
Copied contents to your clipboard!